Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real‐World Propensity Score–Matched Analysis
Journal of Osteoporosis · 2026-01 · 2026 (1)
DOI: 10.1155/joos/2813928 ↗Abstract
Introduction Romosozumab is a dual antiresorptive/anabolic monoclonal antibody against sclerostin, approved for osteoporosis. Largely driven by the ARCH trial, unexpected concerns for cardiovascular safety arose, mandating a black‐box warning. Despite numerous subsequent investigations, the true nature of this association is unelucidated. Materials and Methods Real‐world data were analyzed through TriNetX network, further clarifying this association. Over 1 year, we analyzed patients aged > 50 with osteoporosis, exposed to romosozumab (Cohort A) or teriparatide/abaloparatide (Cohort B), with propensity score matching. We did not exclude patients with outcomes of interest prior to the index event. Results We observed a significant association with lower hazard ratios among four‐ (HR 0.441, 95% CI 0.0.376–0.638, p < 0.0001) and three‐point major adverse cardiovascular events (HR 0.624, 95% CI 0.567–0.688, p < 0.0001), with improved survival probabilities among Cohort A. Romosozumab participants continued to demonstrate a significantly lower hazard (and improved survival probabilities) of myocardial infarction, heart failure, and death, but no significant difference was observed with respect to cerebrovascular accidents. Subsequent E‐value sensitivity analyses suggested moderate robustness to unmeasured confounding. Further subgroup analyses were performed over two and five years of follow‐up, among patients aged 50–64 and > 65, along with male‐ and female‐only cohorts. Conclusion The true association between romosozumab and cardiovascular events remains unknown. Additional studies of a prospective nature are required to investigate this further. These findings do not demonstrate a clear increased cardiovascular risk signal in a real‐world setting; however, they should be interpreted as associative rather than causal and are not sufficient to change current regulatory recommendations.
EUVIMED